EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

SARS-CoV-2 inhibits EBV-dependent tumor proliferation through PLpro-mediated degradation of EBNA1

Liubing Du, Mengxuan Wang, Xue Liu, Ziliang Peng, Zhihui Zhang, Zhanjia Zhang, Zhijuan Liang, Qingrong Sun, Jiaxin Zhuang, Kongyang Ma, Yao-Qing Chen, Panpan Hou und 4 weitere

Acta Pharmaceutica Sinica B · 2026-11 · 16 (11) · 7418-7433

DOI: 10.1016/j.apsb.2026.07.042 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Pharmaceutica Sinica B, 2026-11. Verfasst von Liubing Du und 15 weiteren Autor:innen. Beteiligte Einrichtung: The Molecular Cancer Research Center, School of Medicine, Shenzhen Campus of Sun Yat-sen University, Shenzhen 518107, China. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health Commission of the People's Republic of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

Anti-EBV tumor therapyCOVID-19EBNA1EBVEBV reactivationPLproProtease activity assayProtein degradationSARS-CoV-2Viral co-circulation

Autor:innen und Institutionen

  • The Molecular Cancer Research Center, School of Medicine, Shenzhen Campus of Sun Yat-sen University, Shenzhen 518107, China.
  • The Division of Basic Research, Guangzhou National Laboratory, Bio-island, Guangzhou 510320, China.
  • The Center for Infection and Immunity Study, School of Medicine, Shenzhen Campus of Sun Yat-sen University, Shenzhen 518107, China.
  • School of Public Health (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Shenzhen 518107, China.
  • State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou…
  • Shenzhen Key Laboratory for Systems Medicine in Inflammatory Diseases, School of Medicine, Shenzhen Campus of Sun Yat-sen University, Shenzhen 518107, China.

Förderung

  • National Health Commission of the People's Republic of China

Zitieren

APA

Du, L., Wang, M., Liu, X., Peng, Z., Zhang, Z., Zhang, Z., Liang, Z., Sun, Q., Zhuang, J., Ma, K., Chen, Y. Q., Hou, P., Zhang, H., Guo, D., Pan, J. A., & Peng, X. (2026). SARS-CoV-2 inhibits EBV-dependent tumor proliferation through PLpro-mediated degradation of EBNA1. Acta Pharmaceutica Sinica B, 16(11), 7418-7433. https://doi.org/10.1016/j.apsb.2026.07.042

Vancouver

Du L, Wang M, Liu X, Peng Z, Zhang Z, Zhang Z, et al. SARS-CoV-2 inhibits EBV-dependent tumor proliferation through PLpro-mediated degradation of EBNA1. Acta Pharmaceutica Sinica B. 2026;16(11):7418-7433. doi:10.1016/j.apsb.2026.07.042

BibTeX
@article{Du2026,
  author = {Du, Liubing and Wang, Mengxuan and Liu, Xue and Peng, Ziliang and Zhang, Zhihui and Zhang, Zhanjia and Liang, Zhijuan and Sun, Qingrong and Zhuang, Jiaxin and Ma, Kongyang and Chen, Yao-Qing and Hou, Panpan and Zhang, Hua and Guo, Deyin and Pan, Ji-An and Peng, Xiaoxue},
  title = {SARS-CoV-2 inhibits EBV-dependent tumor proliferation through PLpro-mediated degradation of EBNA1},
  journal = {Acta Pharmaceutica Sinica B},
  year = {2026},
  volume = {16},
  number = {11},
  pages = {7418--7433},
  doi = {10.1016/j.apsb.2026.07.042}
}
Kostenlos starten →